Life Extension Magazine®

Issue: Oct 2010

Block Absorption of Fat Calories Safely

A landmark study reveals that for a majority of individuals, regular dieting is a cause of weight gain and may increase your long-term risk of chronic disease. Interventions that block uptake of killer fat calories are more effective—when used the right way. Here we detail how to benefi t from lipase-inhibitors and bile acid-binders while maintaining optimal levels of fat-soluble nutrients, like vitamins E, D, and K.

By Julius Goepp, MD.

Reverse Age-Related Weight Gain

Of all the available strategies to induce long-term weight loss and combat obesity, dieting may be the least effective. Even worse, regular dieting has been shown to be a strong predictor of future weight gain and increased risk of chronic disease.1

In the most rigorous and comprehensive analysis of dieting outcomes to date, a groundbreaking UCLA study revealed that a majority of dieters not only regain lost weight after dieting—they put on even more weight.1 The researchers also found evidence to suggest that repeatedly losing and gaining weight (so-called “yo-yo” dieting) is linked to increased risk of cardiovascular disease, stroke, diabetes, and altered immune function.2

Fortunately, there are safe, effective interventions to help reduce fat uptake while gradually lowering your overall calorie burden.

One of these is a drug that blocks the absorption of ingested fats by inhibiting lipase, the enzyme that breaks down dietary fat in the intestine. The lipase inhibitor orlistat (brand name Xenical® and alli®) has been clinically proven to block fat absorption in the digestive tract.3-5 Life Extension® has advocated a 60- to 90-day course of orlistat to limit one’s exposure to fat calories while gradually making the necessary dietary changes and other modifications to facilitate optimal weight loss. Green tea extracts also help block lipase activity, though not as potently as orlistat.

How Orlistat Works

Another strategy that may be used with orlistant/green tea or by itself is to consume a special fiber called propolmannan before heavy meals. Propolmannan binds bile acids in the small intestine that would otherwise help facilitate dietary fat absorption into the bloodstream. When taken before meals, propolmannan forms a viscous sponge that can help further reduce the impact of excess calories.

When taking drugs or nutrients that impede fat absorption, it is important to ensure that you continue to absorb vital fat-soluble nutrients such as vitamin D, vitamin K, vitamin E and the omega-3s. Since fat normally shuttles these nutrients into the bloodstream, you should make sure to take these nutrients at the time of day that ensures maximum absorption.

Here we detail how orlistat works to diminish your exposure to killer fat calories. You will also learn how it decreases your body’s absorption of the fat-soluble vitamins D, E, and K. We will then show how to maintain optimal intake of these key nutrients while obtaining the benefit of lipase inhibitors.

How Orlistat Works

To absorb fats, your body needs to break them down in the intestinal tract. It does so partially by the action of an enzyme produced in the pancreas that converts triglycerides in ingested dietary fats to monoglycerides and free fatty acids. The name of this enzyme that breaks down fat is lipase.

Once acted on by lipase, ingested fat molecules are transported via the bloodstream to the membranes of adipose or muscle cells, bringing calories and health risks with them. As a lipase inhibitor, orlistat reduces fat absorption by as much as 30%.5

This has two important effects. Of course, the unabsorbed fat eventually passes out of the body. Just as importantly, if you don’t cut back on the amount of fat you eat, the lack of absorption will produce some very unpleasant side effects, such as bloating, diarrhea, and even fecal soiling. The result, to quote the manufacturer, is that orlistat “helps your head learn healthy habits that stick… to teach your body a new, healthier way of eating.”6 In other words, you become conditioned to eat less fat so you’ll stay comfortable. The ultimate objective is to provide an incentive to ingest fewer fat calories.

Orlistat is effective. A two-year European study found a mean decrease in body weight of 10.2% in the orlistat group compared to 6.1% in the placebo group at 1 year.5 And 9.3% of the orlistat group lost more than 20% of their initial weight, versus 2.1% of the placebo group. But there’s a downside.

All that fat the body didn’t absorb? It carried with it essential vitamins that can only dissolve in fat—the fat-soluble vitamins A, D, E, and K. Clinical trials show that orlistat may induce malabsorption of fat-soluble vitamins to varying degrees, often resulting in the need to supplement patients to maintain normal blood levels.7-11 In fact, orlistat can reduce absorption of vitamin E by as much as 60%.11 This has led to expert recommendations that people taking orlistat should supplement with fat-soluble vitamins.8,12 That’s true even if they are already taking a daily multivitamin.13

Vitamin D

Vitamin D was long associated only with calcium absorption and bone health, and indeed it is vital in those areas. In fact, existing recommended daily amounts of vitamin D were developed originally to help sustain adequate levels of calcium in blood and bone. In recent years, however, we’ve learned that vitamin D has essential effects throughout the body.14,15 In fact, vitamin D receptors are found in most body tissues, indicating the fundamental importance of this vitamin.16

Vitamin D

For instance, vitamin D has profound neurocognitive effects. Insufficient vitamin D levels are associated with low mood and poorer cognitive performance in adults.17,18 Older adults in particular are at risk for cognitive impairment when they lack sufficient vitamin D.19 And low vitamin D levels are associated with frailty among older adults as well.20 On the other hand, there’s supportive evidence that adequate vitamin D levels may help prevent Alzheimer’s disease and other devastating forms of cognitive decline.21

A recent discovery is that vitamin D has profound impact on the immune system.22 Vitamin D insufficiency is associated with increased vulnerability to influenza, and many studies show that supplementing with vitamin D helps prevent the flu.23,24 Experts now strongly recommend testing and treating for vitamin D deficiency as part of a swine flu prevention strategy.25

Astonishingly, because of antiquated reference values for how much vitamin D we should take, a tremendous number of American adults are already vitamin D deficient or insufficient when blood levels are checked. Obese people—the very people who take orlistat—are even more likely to be deficient in vitamin D.26 Daily multivitamins don’t provide nearly enough vitamin D to sustain healthy levels. Experts recommend 2,000-7,000 IU vitamin D per day to maintain year-round adequate levels between 40-70 ng per mL.27

Vitamin E

Vitamin E is the primary fat-soluble antioxidant in mammals, making it essential in preventing oxidative damage to lipid-rich cell membranes.28 As a result, vitamin E can prevent or mitigate oxidant-related diseases such as atherosclerosis, strokes, and many cancers.29,30 But vitamin E is now known to have many other health-giving properties as well, including intra- and inter-cellular signaling and regulation of gene expression.31-33 In fact, people with lifelong generous dietary vitamin E intakes enjoy substantial reductions in their risk of chronic disease.34 Tragically, more than 90% of Americans do not consume the recommended dietary amounts of 15 mg/day (22.5 IU/day).34 Decreased absorption resulting from orlistat use will only exacerbate the risk.35 And the effects are immediate and profound.

Lung, kidney, and colon tissue are all vulnerable to vitamin E depletion, predisposing to diseases in those organs.36-39 Low plasma concentrations of the gamma-tocopherol form of vitamin E are associated with increased rates of cardiovascular disease.40,41

Advancing age itself causes an increase in protein oxidation in memory-related brain regions—one of many reasons our memories begin to weaken with time.42 Vitamin E can prevent such changes in laboratory studies of older animals.42,43 In fact, people with high plasma levels of vitamin E were found in 2010 to have reduced incidence of Alzheimer’s disease.44

Finally, vitamin E, particularly in the form of gamma-tocopherol, is a powerful inducer of apoptosis (programmed cell death) in cancer cells.45 Gamma-tocopherol-rich supplements inhibit colon, prostate, mammary, and lung tumorigenesis in animal models, making them attractive as chemoprevention agents.46

Which Vitamin E Are You Taking?

“Vitamin E” is a catch-all term for a group of 8 related molecules called tocopherols and tocotrienols.47 Alpha-tocopherol is the form that has received most of the attention, but recent data suggest that gamma-tocopherol may have greater health benefits.40,48 Gamma-tocopherol has potent anti-inflammatory and antioxidant properties, and in fact is more effective at scavenging free radicals and nitrogen species than the more common alpha form.49,50 Supplementation with alpha-tocopherol decreases tissue concentrations of gamma-tocopherol. Fortunately, supplementation with gamma-tocopherol increases concentrations of both alpha- and gamma-tocopherols.40 Regardless of the form, impaired fat absorption resulting from orlistat use depletes the body of vitamin E, making supplementation vital.

What You Need to Know: Essential Fat-Soluble Nutrients
  • Essential Fat-Soluble Nutrients
    Dieting is both ineffective for long-term weight loss as well as being dangerous.
  • Repeated dieting is a risk factor for cardiovascular disease, stroke, diabetes, and altered immune function.
  • The lipase inhibitor orlistat effectively blocks the body’s ability to absorb fat. Since it decreases absorption of key fat-soluble vitamins, it is of paramount importance to concurrently supplement with fat-soluble vitamins including D, E, and K while using orlistat.

Vitamin K

Vitamin K

Vitamin K was first discovered for its role in the blood coagulation system. Overt deficiencies in vitamin K produce dangerous bleeding disorders. More recently we’ve learned that vitamin K (like D and E) has a host of other critical functions that are less obvious but no less dangerous. Vitamin K is a crucial factor for enzymes that modify important structural proteins throughout the body.51,52 That makes vitamin K essential for functions in addition to blood clotting, such as bone development, cellular signaling, and growth control, including cancers.52,53 But large segments of the adult population already don’t get adequate vitamin K to support those critical processes.53,54 Further depletion of vitamin K by orlistat, therefore, puts you in danger of losing essential vitamin K-dependent functions.10

Of greatest concern is that vitamin K deficiency (or depletion) is associated both with blood vessel calcification and with osteoporosis.55 That’s because vitamins D and K interact in a delicate ballet to determine where calcium winds up in your body.56 At the right levels, it goes into bone, preventing osteoporosis. But with deficiency of vitamin K, the opposite happens. Calcium leaves bone, instead becoming deposited in arterial walls.56 Indeed, normal cells in the vessel wall transform into bone-forming cells—essentially turning your arteries into bone!57,58 Meanwhile, in bone tissue the effects of vitamin K depletion are the opposite—low K levels are associated with calcium loss, lower bone mass and increased fracture risk.59

 People with high plasma levels of vitamin E were found in 2010 to have reduced incidence of Alzheimer’s disease.

Fortunately, supplementation with the proper form of vitamin K can help prevent consequences of vitamin K depletion. A supplement containing both vitamins D and K had a beneficial effect on the elasticity of arterial walls.60 And in people who already have coronary arterial calcification, vitamin K supplementation can prevent progression of the disease.61 Indeed, high intake of vitamin K2 (menaquinone) is associated with lower overall risk of death from coronary heart disease.62

Vitamin supplementation with menaquinone (K2) is also protective against osteoporosis and fractures.62,63 It helps reduce blood levels of bone-resorption markers and increases markers of bone formation.64 Vitamin K supplementation also enhances overall bone metabolism in active women65 and improves bone geometry and strength in postmenopausal women.66


omega-3 fatty acids

A groundbreaking study conclusively demonstrated that dieting is not only ineffective; it can also be dangerous. Repeated dieting is a risk factor for cardiovascular disease, stroke, diabetes, and altered immune function.

Life Extension recommends that in lieu of dieting, an effort should be made to adjust one’s food intake to gradually reduce the number of calories ingested each day.

The lipase inhibitor orlistat and the special fiber propolmannan can help facilitate the effects of a modestly reduced fat calorie diet by helping to impede absorption of some fat calories.

Since impeding dietary fats can also reduce absorption of fat-soluble nutrients (including vital omega-3 fatty acids), you should adjust your supplement regiment to make sure you take these nutrients at a time of the day furthest removed from your last dose of orlistat and/or propolmannan.

If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at


1. Mann T, Tomiyama AJ, Westling E, Lew AM, Samuels B, Chatman J. Medicare’s search for effective obesity treatments: diets are not the answer. Am Psychol. 2007 Apr;62(3):220-33.

2. Available at: Accessed June 21, 2010.

3. de Castro JJ, Dias T, Chambel P, et al. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia. Rev Port Cardiol. 2009 Dec;28(12):1361-74.

4. McClendon KS, Riche DM, Uwaifo GI. Orlistat: current status in clinical therapeutics. Expert Opin Drug Saf. 2009 Nov;8(6):727-44.

5. Harp JB. Orlistat for the long-term treatment of obesity. Drugs Today (Barc). 1999 Feb;35(2):139-45.

6. Available at: Accessed June 16, 2010.

7. Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000 Mar;24(3):306-13.

8. Gotfredsen A, Westergren Hendel H, Andersen T. Influence of orlistat on bone turnover and body composition. Int J Obes Relat Metab Disord. 2001 Aug;25(8):1154-60.

9. O’Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess. 2001;5(18):1-81.

10. MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. Ann Pharmacother. 2003 Apr;37(4):510-2.

11. Ozcelik O, Ozkan Y, Karatas F, Kelestimur H. Exercise training as an adjunct to orlistat therapy reduces oxidative stress in obese subjects. Tohoku J Exp Med. 2005 Aug;206(4):313-8.

12. McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002 Jul;22(7):814-22.

13. McDuffie JR, Calis KA, Uwaifo GI, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res. 2002 Jul;10(7):642-50.

14. Stechschulte SA, Kirsner RS, Federman DG. Vitamin D: bone and beyond, rationale and recommendations for supplementation. Am J Med. 2009 Sep;122(9):793-802.

15. Barnard K, Colon-Emeric C. Extraskeletal effects of vitamin D in older adults: cardiovascular disease, mortality, mood, and cognition. Am J Geriatr Pharmacother. 2010 Feb;8(1):4-33.

16. Verstuyf A, Carmeliet G, Bouillon R, Mathieu C. Vitamin D: a pleiotropic hormone. Kidney Int. 2010 Feb 24.

17. Wilkins CH, Sheline YI, Roe CM, Birge SJ, Morris JC. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry. 2006 Dec;14(12):1032-40.

18. Buell JS, Dawson-Hughes B, Scott TM, et al. 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology. 2010 Jan 5;74(1):18-26.

19. Annweiler C, Schott AM, Allali G, et al. Association of vitamin D deficiency with cognitive impairment in older women: cross-sectional study. Neurology. 2010 Jan 5;74(1):27-32.

20. Wilhelm-Leen ER, Hall YN, Deboer IH, Chertow GM. Vitamin D deficiency and frailty in older Americans. J Intern Med. 2010 Apr 28.

21. Evatt ML, Delong MR, Khazai N, Rosen A, Triche S, Tangpricha V. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008 Oct;65(10):1348-52.

22. Bikle DD. Vitamin D and the immune system: role in protection against bacterial infection. Curr Opin Nephrol Hypertens. 2008 Jul;17(4):348-52.

23. Faumuina R, Bilbao J, Aspy CB, Mold JW. Is vitamin D deficiency associated with a greater likelihood of contracting influenza? J Okla State Med Assoc. 2010 Apr-May;103(4-5):118-9.

24. Cannell JJ, Zasloff M, Garland CF, Scragg R, Giovannucci E. On the epidemiology of influenza. Virol J. 2008;5:29.

25. Edlich RF, Mason SS, Dahlstrom JJ, Swainston E, Long WB, 3rd, Gubler K. Pandemic preparedness for swine flu influenza in the United States. J Environ Pathol Toxicol Oncol. 2009;28(4):261-4.

26. Herranz Antolin S, Garcia Martinez MD, Alvarez De Frutos V. Vitamin D deficiency in morbidly obese patients. A case-control study. Endocrinol Nutr. 2010 May 20.

27. Cannell JJ, Hollis BW. Use of vitamin D in clinical practice. Altern Med Rev. 2008 Mar;13(1):6-20.

28. Schneider C. Chemistry and biology of vitamin E. Mol Nutr Food Res. 2005 Jan;49(1):7-30.

29. Blum S, Vardi M, Brown JB, et al. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics. 2010 May;11(5):675-84.

30. Shah FD, Patel JB, Shukla SN, Shah PM, Patel PS. Evaluation of plasma non-enzymatic antioxidants in breast cancer etiology. Asian Pac J Cancer Prev. 2009 Jan-Mar;10(1):91-6.

31. Zingg JM. Vitamin E: an overview of major research directions. Mol Aspects Med. 2007 Oct-Dec;28(5-6):400-22.

32. Tolle A, Schlame M, Charlier N, Guthmann F, Rustow B. Vitamin E differentially regulates the expression of peroxiredoxin-1 and -6 in alveolar type II cells. Free Radic Biol Med. 2005 May 15;38(10):1401-8.

33. Johnson A, Manor D. The transcriptional signature of vitamin E. Ann N Y Acad Sci. 2004 Dec;1031:337-8.

34. Traber MG, Frei B, Beckman JS. Vitamin E revisited: do new data validate benefits for chronic disease prevention? Curr Opin Lipidol. 2008 Feb;19(1):30-8.

35. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol. 1996 Jul;36(7):647-53.

36. Sabat R, Guthmann F, Rustow B. Formation of reactive oxygen species in lung alveolar cells: effect of vitamin E deficiency. Lung. 2008 Mar-Apr;186(2):115-22.

37. Huang HS, Ma MC, Chen J. Low-vitamin E diet exacerbates calcium oxalate crystal formation via enhanced oxidative stress in rat hyperoxaluric kidney. Am J Physiol Renal Physiol. 2009 Jan;296(1):F34-45.

38. Shimizu MH, Araujo M, Borges SM, de Tolosa EM, Seguro AC. Influence of age and vitamin E on post-ischemic acute renal failure. Exp Gerontol. 2004 May;39(5):825-30.

39. Drew JE, Mercer DK, Mayer C, et al. Oxidative stress in colon tissue induced by vitamin E depletion. Biochem Soc Trans. 2004 Dec;32(Pt 6):979-81.

40. Jiang Q, Christen S, Shigenaga MK, Ames BN. gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention. Am J Clin Nutr. 2001 Dec;74(6):714-22.

41. Minamiyama Y, Takemura S, Hai S, Suehiro S, Okada S. Vitamin E deficiency accelerates nitrate tolerance via a decrease in cardiac P450 expression and increased oxidative stress. Free Radic Biol Med. 2006 Mar 1;40(5):808-16.

42. Jolitha AB, Subramanyam MV, Asha Devi S. Modification by vitamin E and exercise of oxidative stress in regions of aging rat brain: studies on superoxide dismutase isoenzymes and protein oxidation status. Exp Gerontol. 2006 Aug;41(8):753-63.

43. Fukui K, Takatsu H, Shinkai T, Suzuki S, Abe K, Urano S. Appearance of amyloid beta-like substances and delayed-type apoptosis in rat hippocampus CA1 region through aging and oxidative stress. J Alzheimers Dis. 2005 Dec;8(3):299-309.

44. Mangialasche F, Kivipelto M, Mecocci P, et al. High plasma levels of vitamin E forms and reduced Alzheimer’s disease risk in advanced age. J Alzheimers Dis. 2010 Apr 22.

45. Yu W, Park SK, Jia L, et al. RRR-gamma-tocopherol induces human breast cancer cells to undergo apoptosis via death receptor 5 (DR5)-mediated apoptotic signaling. Cancer Lett. 2008 Feb 8;259(2):165-76.

46. Ju J, Picinich SC, Yang Z, et al. Cancer-preventive activities of tocopherols and tocotrienols. Carcinogenesis. 2010 Apr;31(4):533-42.

47. Sen CK, Khanna S, Roy S. Tocotrienols: Vitamin E beyond tocopherols. Life Sci. 2006 Mar 27;78(18):2088-98.

48. Sen CK, Khanna S, Rink C, Roy S. Tocotrienols: the emerging face of natural vitamin E. Vitam Horm. 2007;76:203-61.

49. Dietrich M, Traber MG, Jacques PF, Cross CE, Hu Y, Block G. Does gamma-tocopherol play a role in the primary prevention of heart disease and cancer? A review. J Am Coll Nutr. 2006 Aug;25(4):292-9.

50. Usoro OB, Mousa SA. Vitamin E forms in Alzheimer’s disease: a review of controversial and clinical experiences. Crit Rev Food Sci Nutr. 2010 May;50(5):414-9.

51. Wallin R, Wajih N, Greenwood GT, Sane DC. Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev. 2001 Jul;21(4):274-301.

52. Berkner KL. The vitamin K-dependent carboxylase. Annu Rev Nutr. 2005;25:127-49.

53. Kaneki M, Hosoi T, Ouchi Y, Orimo H. Pleiotropic actions of vitamin K: protector of bone health and beyond? Nutrition. 2006 Jul-Aug;22(7-8):845-52.

54. McCann JC, Ames BN. Vitamin K, an example of triage theory: is micronutrient inadequacy linked to diseases of aging? Am J Clin Nutr. 2009 Oct;90(4):889-907.

55. Okura T, Kurata M, Enomoto D, et al. Undercarboxylated osteocalcin is a biomarker of carotid calcification in patients with essential hypertension. Kidney Blood Press Res. 2010;33(1):66-71.

56. Schurgers LJ, Cranenburg EC, Vermeer C. Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost. 2008 Oct;100(4):593-603.

57. Krueger T, Westenfeld R, Schurgers L, Brandenburg V. Coagulation meets calcification: the vitamin K system. Int J Artif Organs. 2009 Feb;32(2):67-74.

58. Massry SG, Smogorzewski M. Management of vascular calcification in CKD patients. Semin Nephrol. 2006 Jan;26(1):38-41.

59. Shea MK, Booth SL. Update on the role of vitamin K in skeletal health. Nutr Rev. 2008 Oct;66(10):549-57.

60. Braam LA, Hoeks AP, Brouns F, Hamulyak K, Gerichhausen MJ, Vermeer C. Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: a follow-up study. Thromb Haemost. 2004 Feb;91(2):373-80.

61. Shea MK, O’Donnell CJ, Hoffmann U, et al. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am J Clin Nutr. 2009 Jun;89(6):1799-807.

62. Erkkila AT, Booth SL. Vitamin K intake and atherosclerosis. Curr Opin Lipidol. 2008 Feb;19(1):39-42.

63. Iwamoto J, Matsumoto H, Takeda T. Efficacy of menatetrenone (vitamin K2) against non-vertebral and hip fractures in patients with neurological diseases: meta-analysis of three randomized, controlled trials. Clin Drug Investig. 2009;29(7):471-9.

64. Vermeer C, Gijsbers BL, Craciun AM, Groenen-van Dooren MM, Knapen MH. Effects of vitamin K on bone mass and bone metabolism. J Nutr. 1996 Apr;126(4 Suppl):1187S-91S.

65. Craciun AM, Wolf J, Knapen MH, Brouns F, Vermeer C. Improved bone metabolism in female elite athletes after vitamin K supplementation. Int J Sports Med. 1998 Oct;19(7):479-84.

66. Knapen MH, Schurgers LJ, Vermeer C. Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos Int. 2007 Jul;18(7):963-72.

Subscribe to Life Extension Magazine®

Subscribe Now

Advertise in Life Extension Magazine®

Learn More